secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immuneering Corp (IMRX)
CIK:        0001790340
Form:       8-K
Filed at:   2025-01-07T23:59:59+00:00
Accession:  0001790340-25-000012
Event type: other_material
Sentiment:  positive
Materiality: 0.82
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Immuneering reports 43% ORR in first-line pancreatic combo; plans new trials in 2025
--------------------------------------------------------------------------------

- IMM-1-104 + mGnP in 1L pancreatic: 1 complete response, 2 partial response (43% ORR), 86% DCR among 7 evaluable patients.
- IMM-1-104 + mFFX in 1L pancreatic: all 4 patients had tumor shrinkage; 1 partial response with 100% target lesion reduction.
- IMM-1-104 monotherapy in 2L pancreatic: 11 of 21 evaluable patients achieved disease control; 1 partial response with 67% reduction.
- IMM-6-415 Phase 1 PK/PD: up to 77% pERK inhibition; generally well tolerated with no dose-limiting toxicities.
- Additional Phase 2a data expected Q2 2025; plans to launch arms in melanoma and NSCLC with combinations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1790340/000179034025000012/0001790340-25-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1790340/000179034025000012/imrx-20250107.htm
  HTML page:      https://secwatch.observer/filing/0001790340-25-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer